Research programme: cystic fibrosis gene therapies- Pfizer/University of Iowa

Drug Profile

Research programme: cystic fibrosis gene therapies- Pfizer/University of Iowa

Latest Information Update: 02 Sep 2016

Price : $50

At a glance

  • Originator Pfizer; University of Iowa Research Foundation
  • Class Gene therapies
  • Mechanism of Action Gene transference; Immunomodulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Research Cystic fibrosis

Most Recent Events

  • 04 Feb 2016 Early research in Cystic fibrosis in USA (Parenteral)
  • 04 Feb 2016 University of Iowa research Foundation and Pfizer finalised a licensing agreement for the development of gene therapies in USA for Cystic fibrosis
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top